CalciMedica, Inc. received confirmation from Nasdaq that it complies with the alternative minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), closing its non-compliance notice regarding market value of listed securities. The company previously implemented a one-for-five reverse stock split on August 28, 2026, to address this issue. However, CalciMedica remains in violation of the minimum bid price requirement and has until September 14, 2026, to regain compliance. The filing notes that there is no assurance the company will maintain listing standards. CalciMedica operates in the biotechnology industry, developing therapies for inflammatory diseases.

CalciMedica held its 2026 Annual Meeting of Stockholders on August 19, 2026. Shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 7,500,000 and adjusting reserve calculations for convertible securities. The board ratified Baker Tilly US, LLP as independent auditor and received advisory approval for executive compensation frequency set to annually through 2032. Crucially, shareholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-10 at the Board's discretion, alongside a corresponding reduction in authorized shares. Stockholders also authorized the issuance of Series A and B Warrants for up to 18,673,429 common shares each under a June 23, 2026 Securities Purchase Agreement, including warrants to directors and officers. CalciMedica operates in the biotechnology industry, developing therapies for inflammatory diseases.

CalciMedica reported a net loss of $2.7 million for the first half of 2026, or $0.16 per share, compared to a $11.0 million loss in the prior year period. The company holds $18.6 million in cash and expects funding into late 2027. On June 24, 2026, CalciMedica completed a private placement raising up to approximately $49 million, including $15 million upfront, to advance its pulmonary hypertension strategy. The company plans a Phase 1b trial for Auxora in pulmonary arterial hypertension and anticipates an IND submission for oral candidate CM5480 in mid-2027. Additionally, the FDA aligned on the primary endpoint for the Phase 2b trial of Auxora in acute pancreatitis, which will measure reduction in new-onset severe respiratory failure. CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies.

CalciMedica, Inc. entered into a securities purchase agreement for a private placement of 18,673,429 units at a purchase price of approximately $0.80 per unit, expected to raise up to $15 million in gross proceeds and up to $34 million in additional proceeds from warrant exercises. The company plans to use the funds to advance its pulmonary hypertension strategy and fund research and development. CalciMedica, Inc. is a biotechnology company focused on developing CRAC channel inhibitors for various diseases.

CalciMedica, Inc. entered into a First Amendment to Loan Documents with Avenue Venture Opportunities Fund II, L.P. to amend a $10,000,000 loan agreement. The amendment extends the interest-only period to September 30, 2027, and the maturity date to September 1, 2029, while increasing the final payment fee by $200,000. Additionally, the company issued a new warrant to purchase 1,000,000 shares at $1.00 per share and amended an existing warrant to decrease its exercise price from $2.32 to $1.00. CalciMedica, Inc. is a biotechnology company focused on developing therapeutic solutions for inflammatory and regenerative medicine.